Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer

Aurelia Vattai; Vincent Cavailles; Sophie Sixou; Susanne Beyer; Christina Kuhn; Mina Peryanova; Helene Heidegger; Kerstin Hermelink; Doris Mayr; Sven Mahner; Christian Dannecker; Udo Jeschke; Bernd Kost

doi:10.18632/oncotarget.22187

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer

Aurelia Vattai, Vincent Cavailles, Sophie Sixou, Susanne Beyer, Christina Kuhn, Mina Peryanova, Helene Heidegger, Kerstin Hermelink, Doris Mayr, Sven Mahner, Christian Dannecker, Udo Jeschke _ and Bernd Kost

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:105356-105371. https://doi.org/10.18632/oncotarget.22187

Metrics: PDF 1471 views | HTML 2334 views | ?

Abstract

Aurelia Vattai1, Vincent Cavailles2, Sophie Sixou3, Susanne Beyer1, Christina Kuhn1, Mina Peryanova1, Helene Heidegger1, Kerstin Hermelink1, Doris Mayr4, Sven Mahner1, Christian Dannecker1, Udo Jeschke1 and Bernd Kost1

1Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, 80337 Munich, Germany

2Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université Montpellier, F-34298 Montpellier, France

3Université Toulouse III - Paul Sabatier, F-31062 Toulouse, France

4Department of Pathology, Ludwig-Maximilians University of Munich, 81337 Munich, Germany

Correspondence to:

Udo Jeschke, email: [email protected]

Keywords: cervical carcinoma; squamous cell carcinoma; adenocarcinoma; RIP140/NRIP1; LCoR

Received: May 18, 2017 Accepted: July 25, 2017 Published: October 31, 2017

ABSTRACT

Introduction: RIP140 (Receptor Interacting Protein) is involved in the regulation of oncogenic signaling pathways and in the development of breast and colon cancers. The aim of the study was to analyze the expression of RIP140 and its partner LCoR in cervical cancers, to decipher their relationship with histone protein modifications and to identify a potential link with patient survival.

Methods: Immunohistochemical analyses were carried out to quantify RIP140 and LCoR expression in formalin-fixed paraffin-embedded tissue sections cervical cancer samples. Correlations of RIP140 and LCoR expression with histopathological variables were determined by correlation analyses. Survival rates of patients expressing low or high levels of RIP140 and LCoR were compared by Kaplan-Meier curves.

Results: RIP140 overexpression was associated with a significantly shorter overall survival of cervical cancer patients. This effect was significant in the squamous cell carcinoma subtype but not in adenocarcinomas. RIP140 is no longer a significant negative prognosticator for cervical cancer when LCoR expression is low.

Discussion: RIP140 is an independent predictor of poor survival of patients with cervical cancer. Patients with tumors expressing low levels of both RIP140 and LCoR showed a better survival compared to patients expressing high levels of RIP140. Modulation of RIP140 and LCoR may represent a novel targeting strategy for cervical cancer prevention and therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22187

Publication Alerts

Research Papers:

Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer

Abstract